Health and Fitness Health and Fitness
Thu, September 6, 2012
[ Thu, Sep 06th 2012 ] - Market Wire
PDL BioPharma Provides Third Quarter 2012 Royalty Revenue Guidance of $85 Million
[ Thu, Sep 06th 2012 ] - Market Wire
Dana-Farber Cancer Institute's Ursula A. Matuloni .. NMD-2076 Published in the European Journal of Can
[ Thu, Sep 06th 2012 ] - Market Wire
Omeros Files Investigational New Drug Application for Lead Compound in PDE10 Program
[ Thu, Sep 06th 2012 ] - Market Wire
Spectrum Pharmaceuticals Completes Acquisition of .. ctive and Swift Integration Expected to Result In
[ Thu, Sep 06th 2012 ] - Market Wire
Teleflex Signs New Innovative Technology Agreemen .. ; VPS®; Vascular Positioning System&re
[ Thu, Sep 06th 2012 ] - Market Wire
Natus to Present at the UBS Global Life Sciences Conference
[ Thu, Sep 06th 2012 ] - Market Wire
Isis Pharmaceuticals Expands Use of BioClinica Express EDC
Wed, September 5, 2012
[ Wed, Sep 05th 2012 ] - Market Wire
Concord Medical Responds to Unusual Market Activity in its Stock
[ Wed, Sep 05th 2012 ] - Market Wire
Hologic Announces Verdict In Patent Infringement Suit
[ Wed, Sep 05th 2012 ] - Market Wire
Neurocrine Biosciences To Present At The Morgan Stanley Global Healthcare Conference
[ Wed, Sep 05th 2012 ] - Market Wire
Abattis Biologix Announces Share Consolidation and Name Change
[ Wed, Sep 05th 2012 ] - Market Wire
Fresenius Medical Care Provides Uninterrupted Car .. for Dialysis Patients Affected by Hurricane Isaac
[ Wed, Sep 05th 2012 ] - Market Wire
PDL BioPharma Announces Conversion Rate Adjustments for Convertible Notes
[ Wed, Sep 05th 2012 ] - Market Wire
NeuroMetrix to Present at Rodman & Renshaw Annual ;Global Investment ;Conference
[ Wed, Sep 05th 2012 ] - Market Wire
Tengion Common Stock to Begin Trading on The OTCQ .. Tier of the OTC Marketplace on September 6, 2012
[ Wed, Sep 05th 2012 ] - Market Wire
Endo Health Solutions to Present at UBS 2012 Global Life Sciences Conference
[ Wed, Sep 05th 2012 ] - Market Wire
BioSpecifics Technologies Corp. Announces 30 Mont .. ety Update for XIAFLEX in Dupuytren's Contracture
[ Wed, Sep 05th 2012 ] - Market Wire
Gilead Sciences to Present at the Morgan Stanley .. Healthcare Conference on Wednesday, September 12
[ Wed, Sep 05th 2012 ] - Market Wire
Navidea Biopharmaceuticals to Present at Upcoming Investor Conferences
[ Wed, Sep 05th 2012 ] - Market Wire
Kindred Healthcare to Participate in the Morgan Stanley Global Healthcare Conference
[ Wed, Sep 05th 2012 ] - Market Wire
Grifols Auszeichnungsgewinner des 9. alljhrlichen .. ALTA Forschungsstipendium bei der 2012 ERS Tagung
[ Wed, Sep 05th 2012 ] - Market Wire
Grifols premia a los ganadores de la 9th Annual eALTA Research Fellowship en la reunin ERS 2012
[ Wed, Sep 05th 2012 ] - Market Wire
Sun Healthcare Group, Inc. Announces Results of S .. s in Connection With Proposed Transaction With Ge
[ Wed, Sep 05th 2012 ] - Market Wire
Herbalife Ltd. to Present at the 2012 Barclays Back-to-School Consumer Conference
[ Wed, Sep 05th 2012 ] - Market Wire
Alexion to Present at Morgan Stanley Global Healthcare Conference
[ Wed, Sep 05th 2012 ] - Market Wire
Ryan & Maniskas, LLP Announces Investigation of Medicis Pharmaceutical Corp.
[ Wed, Sep 05th 2012 ] - Market Wire
Implant Sciences Extends Credit Agreements With D .. Portion of Credit Line Into Convertible Term Loan
[ Wed, Sep 05th 2012 ] - Market Wire
Johnson amp;; Johnson to Participate in Morgan Stanley Global Health Care Conference
[ Wed, Sep 05th 2012 ] - Market Wire
Securities Lawyers Seeking More Money, Information for Stockholders of Medicis at Goldfarb LLP
[ Wed, Sep 05th 2012 ] - Market Wire
XenoPort to Present at the Morgan Stanley Global Healthcare Conference

XenoPort to Present at the Morgan Stanley Global Healthcare Conference


Published on 2012-09-05 07:20:14 - Market Wire
  Print publication without navigation


SANTA CLARA, Calif.--([ ])--XenoPort, Inc. (Nasdaq: XNPT) announced today that it will provide access via the World Wide Web to its presentation at the Morgan Stanley Global Healthcare Conference. The live presentation will occur at 12:00 p.m. Pacific Time (3:00 p.m. Eastern Time) on Tuesday, September 11, 2012. A replay of the presentation will also be available.

To access the live presentation via the Web, please go to [ www.XenoPort.com ]. Please connect to the Website at least 15 minutes prior to the live presentation to ensure adequate time for any software downloads that may be necessary to listen to the Webcast.

A replay of the Webcast can be accessed for a minimum of one month and will be available approximately 24 hours after the live presentation.

About XenoPort

XenoPort is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. Horizant (gabapentin enacarbil) Extended-Release Tablets is approved in the United States for the treatment of moderate-to-severe primary restless legs syndrome (RLS) in adults and for the management of postherpetic neuralgia in adults. GlaxoSmithKline holds commercialization rights and certain development rights for Horizant in the United States. Regnite (gabapentin enacarbil) Extended-Release Tablets is approved and is being marketed for the treatment of RLS in Japan. Astellas Pharma Inc. holds all development and commercialization rights for Regnite in Japan and five other Asian countries. XenoPort holds all other world-wide rights and has co-promotion and certain development rights to gabapentin enacarbil in the United States. XenoPortas pipeline of product candidates includes potential treatments for patients with spasticity, Parkinsonas disease and relapsing-remitting multiple sclerosis (RRMS).

To learn more about XenoPort, please visit the Website at [ www.XenoPort.com ].

XENOPORTand Regnite are registered trademarks of XenoPort, Inc.

Horizant is a registered trademark of GlaxoSmithKline.

XNPT2G

Contributing Sources